目录产品 » 重组蛋白 » SARS-CoV-2 Spike protein (RBD, His & Avi tag)
Manual
SDS
COAs

SARS-CoV-2 Spike protein (RBD, His & Avi tag)

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.
￥3800
Z03483

产品简介
Species SARS-CoV-2
Protein Construction
Spike RBD (Arg319-Ser591)
Accession # P0DTC2		 Avi Poly-His
N-term C-term
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity SARS-CoV-2 Spike protein (RBD, His & Avi tag) can bind with Human ACE2 in functional ELISA assay.
Expression System 293 Cells
Theoretical Molecular Weight 30 kDa
Formulation Supplied as a solution in PBS pH 7.2.
Concentration Please refer to the COA for the specific lot.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles.
返回

图例
SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

»

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

»

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

Western blot analysis of SARS-CoV-2 Spike protein (RBD, His & Avi tag) (GenScript, Z03483) using S1 Antibody(GenScript, A02053).
Lane 1: 10 ng of Z03483
Lane 2: 5 ng of Z03483 »

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

Western blot analysis of SARS-CoV-2 Spike protein (RBD, His & Avi tag) (GenScript, Z03483) using His Antibody(GenScript, A00186).
Lane 1: 10 ng of Z03483
Lane 2: 5 ng of Z03483 »

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

Immobilized ACE-2 Fc Chimera, Human (Cat. No. Z03484) at 2 μg/mL can bind SARS-CoV-2 Spike protein (RBD, His & Avi Tag) (Cat. No. Z03483) with a serial dilution.
THETM His Tag Antibody [HRP], mAb, Mouse (Cat.No.A00612) is used as a secondary antibody (0.1 μg/mL). »

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

Loaded ACE-2 Fc Chimera, Human (CHO-expressed) Protein (Cat. No. Z03516) on Protein A Biosensor, can bind SARS-CoV-2 Spike protein (RBD, His & Avi Tag) (Cat. No. Z03483) with an affinity constant of 12.5 nM as determined in BLI assay. »

SARS-CoV-2 Spike Protein (RBD, His & Avi Tag)

Lane 1: 1μg of SARS-CoV-2 Spike protein (RBD, His & Avi tag), reducing(R)
Lane 2: 3μg of SARS-CoV-2 Spike protein (RBD, His & Avi tag), reducing(R)
Lane 3: 5μg of SARS-CoV-2 Spike protein (RBD, His & Avi tag), reducing(R)
Lane 4: 5μg of SARS-CoV-2 Spike protein (RBD, His & Avi tag), non-reducing(NR)
> 95% as analyzed by SDS-PAGE »

<
>

技术背景
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.
Synonyms SARS-CoV-2 SP RBD; 2019-nCoV SP RBD
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Martin C Runnstrom, et al. Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity. J Allergy Clin Immunol. (2024-06)
Yang Xu, et al. Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines. Vaccines (Basel). (2024-03)
Mohammad Mahdi Hasani-Sadrabadi, et al. Harnessing Biomaterials to Amplify Immunity in Aged Mice through T Memory Stem Cells. ACS Nano. (2024-02)
George Cavic, et al. Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population. Asia Pac J Clin Oncol. (2024-01)
Yuchen Zhou, et al. Delivery of spike-RBD by bacterial type three secretion system for SARS-CoV-2 vaccine development. Front Immunol. (2023-02)
Tasnim Saifudin Zakir, et al. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Viruses. (2022-01)
Tasnim Saifudin Zakir, et al. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Viruses. (2022-01)
Belén Aparicio, et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerg Microbes Infect. (2021-12)
Jianqing Xu, et al. Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral. Front Nutr. (2021-12)
Meng-Li Wu, et al. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduct Target Ther. (2021-12)
Kangli Cao, et al. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol. (2021-12)
Sarunporn Tandhavanant, et al. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE. (2021-08)
Muhammad Ali Ehsan, et al. Screen-Printed Graphene/Carbon Electrodes on Paper Substrates as Impedance Sensors for Detection of Coronavirus in Nasopharyngeal Fluid Samples. Diagnostics (Basel). (2021-06)
Natalie S Haddad, et al. One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. Immunohorizons. (2021-05)
Martin P Steinbuck, et al. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Sci Adv. (2021-02)
Hicks SM, et al. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. The Journal of Infectious Diseases. (2021-01)
Andrei Komarov, et al. Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing. Diagnostics (Basel). (2021-01)
Andrew Cameron, et al. A multiplex microsphere IgG assay for SARS-CoV-2 using ACE2-mediated inhibition as a surrogate for neutralization. J Clin Microbiol. (2020-11)
查看更多
返回